Neurogene Q3 2025: $21M net loss; NGN-401 gene therapy shows 35 skill acquisitions, registrational trial started

Neurogene Inc.

2025-Q3 EPS reported -$3.11 vs consensus -$1.27 ▼ miss (-143.9%)

Net loss of $21.0M for Q3 2025 vs $20.2M in Q3 2024; R&D expenses $17.2M, G&A $6.6M.
Positive interim Phase 1/2 data: 35 developmental milestones/skills acquired across 8 pediatric participants; durable CGI-I gains.
First participant dosed in Embolden registrational trial for Rett syndrome; enrollment expected in 3-6 months.
Cash, equivalents, investments of $265.4M as of Sep 30, 2025; runway through Q1 2028.
Preclinical data showed ICV delivery superior to IT-L for AAV biodistribution in key brain regions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.